Clinical trial
Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and…
NCT00070083 · British Columbia Cancer Agency, Other · Completed
Key facts
| NCT number | NCT00070083 |
|---|---|
| Title | Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma |
| Official title | A Phase I Study Of G3139 Antisense Oligonucleotide (Oblimersen) In Combination With CHOP And Rituximab In Untreated Advanced Stage Diffuse Large B Cell Lymphoma |
| Lead sponsor | British Columbia Cancer Agency, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | oblimersen sodium, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate |
| Start date | Jul 1, 2003 |
| First posted | Oct 7, 2003 |
| Last update posted | Apr 7, 2009 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: